Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01280344
Recruitment Status : Completed
First Posted : January 20, 2011
Last Update Posted : April 13, 2017
Information provided by (Responsible Party):
Helsinn Therapeutics (U.S.), Inc

Brief Summary:
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.

Condition or disease Intervention/treatment Phase
Gastrointestinal Dysmotility Drug: Saline Solution for Injection Drug: Ipamorelin Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis
Actual Study Start Date : April 2011
Actual Primary Completion Date : June 2013
Actual Study Completion Date : May 2014

Arm Intervention/treatment
Experimental: 0.03 mg/kg BID
Ipamorelin 0.03 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
Drug: Ipamorelin
Intravenous (IV)

Experimental: 0.06 mg/kg BID
Ipamorelin 0.06 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
Drug: Ipamorelin
Intravenous (IV)

Experimental: 0.06 mg/kg TID
Ipamorelin 0.06 mg/kg, TID (3 investigational drug infusions)
Drug: Ipamorelin
Intravenous (IV)

Placebo Comparator: Placebo
Matching placebo, TID (3 placebo infusions)
Drug: Saline Solution for Injection
Intravenous (IV)

Primary Outcome Measures :
  1. Recovery of Gastrointestinal (GI) Function [ Time Frame: Up to 10 days ]
    To assess the efficacy of three repeated dose levels of ipamorelin vs. placebo

Secondary Outcome Measures :
  1. Ancillary GI Functions [ Time Frame: Up to 10 days or until hospital discharge ]
    To investigate the effect of ipamorelin on ancillary efficacy measures of GI function and recovery

  2. Number of Subjects with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 14 day outpatient follow-up visit ]
    To investigate the safety and tolerability of ipamorelin laboratory and clinical parameters, incidence of adverse events, until hospital discharge, 14-day outpatient follow-up visit, or until resolution of adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to freely give written informed consent to participate in the study and have signed the Informed Consent Form
  • Males or females, 18 to 85 years of age inclusive at the time of study screening
  • American Society of Anesthesiologists (ASA) Class I-III
  • Have undergone a scheduled small and/or large open partial bowel resection based on a documented incision size greater than or equal to (≥) 10 cm with primary anastomosis
  • Females must not be pregnant as confirmed by a serum pregnancy test at screening and by a urine pregnancy test on the day of surgery
  • Body weight must be between 40-150 kilograms (kg)

Exclusion Criteria:

  • Any procedure which requires a diverting stoma
  • Primary anastomosis not performed at the time of surgery
  • Epidural or intrathecal anesthesia
  • Significant liver disease (ALT and/or total bilirubin > 2-fold upper limits of normal) or kidney disease (serum creatinine > 2.5 mg/dL) at screening
  • History of irritable bowel syndrome
  • Patients with a history of Crohn's disease or ulcerative colitis (UC) who have had multiple GI-related surgeries (Note: surgery naïve Crohn's or UC patients may be included)
  • History of colonic volvulus
  • History of gastroesophageal surgery, gastrectomy, gastric bypass, total colectomy, short bowel syndrome, or multiple complex abdominal surgeries performed by an open procedure (uncomplicated cesarean section and appendectomy would not be considered complex)
  • Patients who have received prior abdominal radiation and/or pelvic radiation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01280344

  Show 45 Study Locations
Sponsors and Collaborators
Helsinn Therapeutics (U.S.), Inc

Responsible Party: Helsinn Therapeutics (U.S.), Inc Identifier: NCT01280344     History of Changes
Other Study ID Numbers: HT-IPAM-202
First Posted: January 20, 2011    Key Record Dates
Last Update Posted: April 13, 2017
Last Verified: April 2017